Business Wire

KAYTUS

Share
KAYTUS Introduces KR1280V2 - a 1U Server with 32 E1.S SSDs, Boosting I/O Performance for LLM Training

KAYTUS, a leading IT infrastructure provider, introduced at ISC High Performance 2024 its high-density computing server KR1280V2. It supports 32 E1.S SSDs, achieving an impressive flash memory density of 512TB in a 1U form factor. Compared to the last generation, KR1280V2 adopts low latency storage and network design, doubling the high concurrency I/O performance for LLM training scenarios, and improving model training efficiency.

This 1U2S flagship server is powered by the latest Intel, AMD, or ARM processors. The KR1280V2 features an optimized cooling strategy to support CPUs with the highest TDP across platforms, without configuration restrictions. It also introduces a novel front I/O configuration, enhancing scalability with 8 PCIe 5.0 expansion cards and improving maintenance efficiency in data centers. The server’s drive tray type has been optimized to offer an innovative storage configuration of 12 front SFF drives, increasing storage density by 20%.

Supports 32 E1.S SSDs without performance degradation, delivering tens of millions IOPS

Powered by 5th Gen Intel® Xeon® processors and boasting remarkable computing density, the KR1280V2 supports up to 32 all-flash E1.S SSDs directly connected to CPUs within a 1U form factor. This configuration harnesses the full I/O rate of PCIe 5.0, maximizing throughput between CPUs and storage, achieving up to 160GB/s storage throughput. With load balancing across two OCP 3.0 cards, it doubles network bandwidth, catering to diverse data storage and processing needs while enhancing overall computing performance by 60%.

With ultimate flash memory density, the KR1280V2 effectively doubles LLMs' high concurrency performance

The KR1280V2 achieves tens of millions of IOPS performance in distributed storage scenarios, marking a remarkable 77% improvement. Deploying KR1280V2 servers for large-scale LLMs training ensures a twofold increase in high-concurrency I/O performance compared to the previous generation. As the number of GPUs and workload increases, the KR1280V2's latency curve becomes smoother and more predictable, demonstrating a notable 13% improvement in data latency also compared to the prior generation. These significant advancements enhance data preparation efficiency, model training, and data management while reducing wasted storage space. Consequently, it delivers robust storage capacity and performance for innovative LLM applications and better supports Java-based business scenarios requiring massive data, low latency, and high concurrency, such as in finance, cloud services, enterprises, and other data center applications.

Optimized cooling technologies and exceptional business reliability and sustainability

In terms of heat dissipation, the KR1280V2 supports multiple cooling methods, including EVAC heatsink air cooling, cold-plated liquid cooling, and single-phase immersion liquid cooling. It achieves an 8% to 12% power reduction through fan partition regulation, one-click BIOS optimization, and other techniques across 17 energy-efficient scenarios. Additionally, the KR1280V2 employs numerous advanced technologies to enhance stability and security. It introduces the exceptional MUPR2.0 early detection memory fault function, which utilizes a more comprehensive memory scrubbing technique to self-check and fix memory faults, achieving a broader range of error correction and a higher level of system protection. Consequently, the system's downtime rate is 69% lower than the industry average.

To learn more about the KAYTUS KR1280V2 high-density server, please visit the website.

About KAYTUS

KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521588996/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye